The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Prospective Minimal Residual Disease Monitoring to Predict Relapse of Acute Promyelocytic Leukemia and to Direct Pre-Emptive Arsenic Trioxide Therapy
Open accessAbstract
Purpose: Molecular diagnostics and early assessment of treatment response that use methodologies capable of detecting submicroscopic disease can distinguish subgroups of patients with leukemia at differing relapse risk. Such information is being incorporated into risk-stratified protocols; however, there are few data concerning prospective use of sequential minimal residual disease (MRD) monitoring to identify more precisely those patients destined to experience relapse, which would allow more tailored therapies. Methods: Real-time quantitative polymerase chain reaction (RQ-PCR) assays to detect leukemia-specific transcripts (ie, PML-RARA, RARA-PML) were used to prospectively analyze 6,727 serial blood and marrow samples from 406 patients with newly diagnosed acute promyelocytic leukemia (APL) who were receiving all-trans-retinoic acid and anthracycline-based chemotherapy. Results: MRD monitoring according to the recommended schedule successfully identified the majority of patients subject to relapse and provided the most powerful predictor of relapse-free survival (RFS) in multivariable analysis (hazard ratio, 17.87; 95% CI, 6.88 to 46.41; P < .0001); MRD monitoring was far superior to presenting WBC (hazard ratio, 1.02; 95% CI, 1.00 to 1.03; P = .02), which is currently widely used to guide therapy. In patients who were predicted to experience relapse on the basis of MRD monitoring, early treatment intervention with arsenic trioxide prevented progression to overt relapse in the majority, and the RFS rate at 1 year from molecular relapse was 73%. By using this strategy, 3-year cumulative incidence of clinical relapse was only 5% in the Medical Research Council AML15 trial. Conclusion: Rigorous sequential RQ-PCR monitoring provides the strongest predictor of RFS in APL and, when coupled with pre-emptive therapy, provides a valid strategy to reduce rates of clinical relapse. This provides a model for development of a more individualized approach to management of other molecularly defined subtypes of acute leukemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Heid, C. A., Stevens, J., Livak, K. J., & Williams, P. M. (1996) · Genome Research · doi:10.1101/gr.6.10.986 · Cited by 6,174
Cheson, B. D., Bennett, J. M., Kopecky, K. J., Büchner, T., Willman, C. L., Estey, E. H., Schiffer, C. A., Doehner, H., Tallman, M. S., Lister, T. A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.036 · Cited by 2,654
Self-citationCreutzig, U., & Kaspers, G. J. L. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.99.116 · Cited by 2,137
Gabert, J., Beillard, E., van der Velden, V. H. J., Bi, W., Grimwade, D., Pallisgaard, N., Barbany, G., Cazzaniga, G., Cayuela, J. M., Cavé, H., et al. (2003) · Leukemia · doi:10.1038/sj.leu.2403135 · Cited by 1,284
Self-citationHughes, T. P., Kaeda, J., Branford, S., Rudzki, Z., Hochhaus, A., Hensley, M. L., Gathmann, I., Bolton, A. E., van Hoomissen, I. C., Goldman, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa030513 · Cited by 1,218
Hughes, T. (2006) · Blood · doi:10.1182/blood-2006-01-0092 · Cited by 1,199
van Dongen, J., Macintyre, E., Gabert, J., Delabesse, E., Rossi, V, Saglio, G., Gottardi, E., Rambaldi, A., Dotti, G., Griesinger, F., et al. (1999) · Leukemia · doi:10.1038/sj.leu.2401592 · Cited by 1,169
Sanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationBorowitz, M. J., Devidas, M., Hunger, S. P., Bowman, W. P., Carroll, A. J., Carroll, W. L., Linda, S., Martin, P. L., Pullen, D. J., Viswanatha, D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-132837 · Cited by 842
United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia
Soignet, S. L., Frankel, S. R., Douer, D., Tallman, M. S., Kantarjian, H., Calleja, E., Stone, R. M., Kalaycio, M., Scheinberg, D. A., Steinherz, P., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3852 · Cited by 826
Shen, Z.-X., Shi, Z.-Z., Fang, J., Gu, B.-W., Li, J.-M., Zhu, Y.-M., Shi, J.-Y., Zheng, P.-Z., Yan, H., Liu, Y.-F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0400053101 · Cited by 583
van der Velden, V. H. J., Hochhaus, A., Cazzaniga, G., Szczepanski, T., Gabert, J., & van Dongen, J. J. M. (2003) · Leukemia · doi:10.1038/sj.leu.2402922 · Cited by 563
Brüggemann, M., Raff, T., Flohr, T., Gökbuget, N., Nakao, M., Droese, J., Lüschen, S., Pott, C., Ritgen, M., Scheuring, U., et al. (2006) · Blood · doi:10.1182/blood-2005-07-2708 · Cited by 537
Estey, E., Garcia-Manero, G., Ferrajoli, A., Faderl, S., Verstovsek, S., Jones, D., & Kantarjian, H. (2006) · Blood · doi:10.1182/blood-2005-10-4006 · Cited by 384
Mathews, V., George, B., Lakshmi, K. M., Viswabandya, A., Bajel, A., Balasubramanian, P., Shaji, R. V., Srivastava, V. M., Srivastava, A., & Chandy, M. (2006) · Blood · doi:10.1182/blood-2005-08-3532 · Cited by 343
Therapy of Molecular Relapse in Acute Promyelocytic Leukemia
Coco, F. L., Diverio, D., Avvisati, G., Petti, M. C., Meloni, G., Pogliani, E. M., Biondi, A., Rossi, G., Carlo-Stella, C., Selleri, C., et al. (1999) · Blood · doi:10.1182/blood.v94.7.2225.419k03_2225_2229 · Cited by 229
Self-citationSchnittger, S., Weisser, M., Schoch, C., Hiddemann, W., Haferlach, T., & Kern, W. (2003) · Blood · doi:10.1182/blood-2003-03-0880 · Cited by 223
Treatment of acute promyelocytic leukemia with arsenic trioxide without ATRA and/or chemotherapy
Ghavamzadeh, A., Alimoghaddam, K., Ghaffari, S. H., Rostami, S., Jahani, M., Hosseini, R., Mossavi, A., Baybordi, E., Khodabadeh, A., Iravani, M., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdj019 · Cited by 200
Mortuza, F. Y., Papaioannou, M., Moreira, I. M., Coyle, L., Gameiro, P., Gandini, D., Prentice, H. G., Goldstone, A. H., Hoffbrand, A. V., & Foroni, L. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.1094 · Cited by 192
Camacho, L. H., Soignet, S. L., Chanel, S., Ho, R., Heller, G., Scheinberg, D. A., Ellison, R., & Warrell, R. P. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2620 · Cited by 174
Marcucci, G., Livak, K., Bi, W., Strout, M., Bloomfield, C., & Caligiuri, M. (1998) · Leukemia · doi:10.1038/sj.leu.2401128 · Cited by 161
Esteve, J., Escoda, L., Martín, G., Rubio, V., Díaz-Mediavilla, J., González, M., Rivas, C., Álvarez, C., Miguel, J. F. S., Brunet, S., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404501 · Cited by 122
Tricks of the trade for the appropriate management of newly diagnosed acute promyelocytic leukemia
Sanz, M. Á., Tallman, M. S., & Lo‐Coco, F. (2004) · Blood · doi:10.1182/blood-2004-09-3475 · Cited by 116
Self-citationEstey, E. H., Giles, F. J., Kantarjian, H., O’Brien, S., Cortes, J., Freireich, E. J., Lopez-Berestein, G., & Keating, M. (1999) · Blood · doi:10.1182/blood.v94.7.2230.419k05_2230_2235 · Cited by 105
Development of Minimal Residual Disease–Directed Therapy in Acute Myeloid Leukemia
Freeman, S. D., Jovanovic, J. V., & Grimwade, D. J. (2008) · Seminars in Oncology · doi:10.1053/j.seminoncol.2008.04.009 · Cited by 99
Self-citationDignat‐George, F., Sabatier, F., Blann, A. D., & Woywodt, A. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.7677 · Cited by 96
Arsenic Trioxide in Patients With Myelodysplastic Syndromes: A Phase II Multicenter Study
Vey, N., Bosly, A., Guerci‐Bresler, A., Feremans, W., Dombret, H., Dreyfus, F., Bowen, D., Burnett, A. K., Dennis, M., Ribrag, V., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.9503 · Cited by 89
Self-citationPathogenesis and management of the bleeding diathesis in acute promyelocytic leukaemia
Falanga, A., & Rickles, F. R. (2003) · Best Practice & Research Clinical Haematology · doi:10.1016/s1521-6926(03)00059-8 · Cited by 75
Treatment of Acute Promyelocytic Leukemia by Retinoids
Fenaux, P., Wang, Z., & Degos, L. (2007) · Current topics in microbiology and immunology · doi:10.1007/978-3-540-34594-7_7 · Cited by 66
The significance of minimal residual disease in patients with t(15;17)
Grimwade, D. J. (2002) · Best Practice & Research Clinical Haematology · doi:10.1053/beha.2002.0189 · Cited by 41
Self-citationFront Line Clinical Trials and Minimal Residual Disease Monitoring in Acute Promyelocytic Leukemia
Lo‐Coco, F., & Ammatuna, E. (2007) · Springer eBooks · doi:10.1007/978-3-540-34594-7_9 · Cited by 23
Self-citation
Cited by
Grimwade, D., Hills, R. K., Moorman, A. V., Walker, H., Chatters, S., Goldstone, A. H., Wheatley, K., Harrison, C. J., Burnett, A. K., & on behalf of the National Cancer Research Institute Adult Leukaemia Working Group (2010) · Blood · doi:10.1182/blood-2009-11-254441 · Cited by 1,938
Self-citationRetinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
Lo-Coco, F., Avvisati, G., Vignetti, M., Thiede, C., Orlando, S. M., Iacobelli, S., Ferrara, F., Fazi, P., Cicconi, L., Di Bona, E., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300874 · Cited by 1,611
Self-citationSchuurhuis, G. J., Heuser, M., Freeman, S., Béné, M.-C., Buccisano, F., Cloos, J., Grimwade, D., Haferlach, T., Hills, R. K., Hourigan, C. S., et al. (2018) · Blood · doi:10.1182/blood-2017-09-801498 · Cited by 1,041
Self-citationSanz, M. A., Grimwade, D., Tallman, M. S., Lowenberg, B., Fenaux, P., Estey, E. H., Naoe, T., Lengfelder, E., Büchner, T., Döhner, H., et al. (2009) · Blood · doi:10.1182/blood-2008-04-150250 · Cited by 947
Self-citationAssessment of Minimal Residual Disease in Standard-Risk AML
Ivey, A., Hills, R. K., Simpson, M. A., Jovanovic, J. V., Gilkes, A., Grech, A., Patel, Y., Bhudia, N., Farah, H., Mason, J., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1507471 · Cited by 845
Self-citation
Metadata
- Authors
- Grimwade, D., Jovanovic, J. V., Hills, R. K., Nugent, E. A., Patel, Y., Flora, R., Diverio, D., Jones, K., Aslett, H., Batson, E., Rennie, K., Angell, R., Clark, R. E., Solomon, E., Lo-Coco, F., Wheatley, K., & Burnett, A. K.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-08-01
- Volume
- 27
- Issue
- 22
- Pages
- 3650-3658
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2169046713
- Cited by
- 356
- References
- 32
- FWCI
- 10.92
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.